Cancer researcher at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer find that can help you, what women respond to anti-estrogen therapy Marker Identifies Breast Cancer Patients most likely respond to tamoxifen.
And ‘Identification of predictive biomarkers in breast cancer improved individualized therapies specifically tailored to each woman cause cancer,’said Hallgeir Rui, Professor of Oncology, Kimmel Cancer Center at Thomas Jefferson University and principal investigator of the study. ‘The absence of the active form of Stat5 could help a group of patients unlikely respond tamoxifen in order to offered alternative and more aggressive treatments. ‘.
This work is an international multi-center collaboration of researchers like Dr. Hallgeir Rui , David Rimm , Craig Shriver and the National Cancer Institute Cooperative Breast Cancer tissue Resource . Continue reading